ContraFect

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ContraFect and other ETFs, options, and stocks.

About CFRX

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides.

CEO

Roger J. Pomerantz

CEORoger J. Pomerantz

Employees

Employees38

Headquarters

Yonkers, New York

HeadquartersYonkers, New York

Founded

2008

Founded2008

Employees

Employees38

CFRX Key Statistics

Market cap

5.96M

Market cap5.96M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

1.28M

Average volume1.28M

High today

$0.1624

High today$0.1624

Low today

$0.146

Low today$0.146

Open price

$0.151

Open price$0.151

Volume

876.78K

Volume876.78K

52 Week high

$4.54

52 Week high$4.54

52 Week low

$0.1275

52 Week low$0.1275

CFRX News

Yahoo Finance 2d

ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections - Yahoo Finance

ContraFect Corporation YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused o...

CFRX Earnings

-$0.51

-$0.34

-$0.17

$0.00

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Mar 23, Pre-Market

ActualExpected Mar 23, Pre-Market